Table 3 Median overall survival durations in subgroups based on combined hENT1 and DPD tumour expression status
From: Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
Treatment arm | Subgroup | Number of patients | Median overall survival (95% CI) months | P value (raw) | P value post Bonferroni correction |
---|---|---|---|---|---|
5-fluorouracil with folinic acid | hENT1-high DPD-high | 9 | 17.3 (0.6–38.0) | 0.81 | 1.000 |
hENT1-high DPD-low | 39 | 26.0 (19.8–30.1) | |||
hENT1-low DPD-high | 17 | 9.7 (5.3–30.4) | 0.002 | 0.014 | |
hENT1-low DPD-low | 47 | 29.2 (19.5–41.9) | |||
Gemcitabine | hENT1-high DPD-high | 12 | 22.3 (9.6–39.5) | 0.060 | 0.360 |
hENT1-high DPD-low | 57 | 26.3 (17.2–33.0) | |||
hENT1-low DPD-high | 11 | 14.0 (9.1–15.7) | 0.730 | 1.000 | |
hENT1-low DPD-low | 38 | 18.0 (7.6–15.3) |